Big pharma, big data: why drugmakers want your health records
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability
March 5, 2018 9:19 AM ESTBofA/Merrill Lynch raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $68.00 (from $64.00) while maintaining a Buy rating, ahead of the company's CM-227 Opdivo+Yervoy data presentation.
Analyst Jason Gerberry notes a positive outlook on the shares, ahead of BMY's CM-227... More
Pfizer (PFE) Reports Collaboration with Neofludics LLC
March 2, 2018 6:02 AM ESTNeofluidics, LLC announced today that it has entered into a collaboration with Pfizer Inc. (NYSE: PFE) that will attempt to create a first-of-its-kind microfluidics-based platform using Neofluidics' proprietary droplet capture technology to evaluate dynamic drug exposure-response relationships.
Standard in vitro studies performed under static conditions do... More
